13.75
0.12 (0.88%)
| Previous Close | 13.63 |
| Open | 14.18 |
| Volume | 210,462 |
| Avg. Volume (3M) | 183,750 |
| Market Cap | 520,663,008 |
| Price / Book | 75.69 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -3.05 |
| Total Debt/Equity (MRQ) | 113.89% |
| Current Ratio (MRQ) | 6.61 |
| Operating Cash Flow (TTM) | -102.25 M |
| Levered Free Cash Flow (TTM) | -62.83 M |
| Return on Assets (TTM) | -39.04% |
| Return on Equity (TTM) | -115.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Celcuity Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.75 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 81.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (Stifel, 736.36%) | Buy |
| Median | 93.50 (580.00%) | |
| Low | 70.00 (Needham, 409.09%) | Buy |
| Average | 93.00 (576.36%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 68.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 13 Nov 2025 | 115.00 (736.36%) | Buy | 81.86 |
| HC Wainwright & Co. | 22 Oct 2025 | 77.00 (460.00%) | Buy | 70.04 |
| 18 Aug 2025 | 66.00 (380.00%) | Buy | 51.57 | |
| Needham | 20 Oct 2025 | 70.00 (409.09%) | Buy | 70.58 |
| 03 Oct 2025 | 70.00 (409.09%) | Buy | 50.51 | |
| Guggenheim | 22 Sep 2025 | 110.00 (700.00%) | Buy | 52.49 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |